The term triple-negative breast cancer (TNBC) defines breast tumors that do not express estrogen receptors, progesterone receptor or epidermal growth factor receptor HER2 on immunohistochemical analysis. TNBC accounts for 12-17% of all types of breast cancer. Molecular profiling indicated that triple-negative breast cancer represents a heterogeneous subgroup of breast cancer. Triple-negative br...

Objective: To investigate the clinicopathological and immunohistochemical features of triple-negative breast cancer. Methods: The clinicopathological and immunohistochemical data (Ki-67, CK5/6, EGFR, E-Ca, SAM, P53, P63, FAS) of 199 female patients who were treated for breast cancer in thyroid and breast surgery of Xiaogan Central Hospital from January 2015 to December 2016 was retrospectively ...

Triple-negative breast cancer (TNBC) is an operational term for breast cancers lacking targetable estrogen receptor expression and HER2 amplifications. TNBC is, therefore, inherently heterogeneous, and is associated with worse prognosis, greater rates of metastasis, and earlier onset. TNBC displays mutational and transcriptional diversity, and distinct mRNA transcriptional subtypes exhibiting u...

This study focused on triple-negative breast cancer (TNBC) that is characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2). The primary goal of this study was to describe the relation between triple-negative receptor status and survival. This is the first study about triple-negative breast cancer in our ...

Familial breast and ovarian cancer prevalence was assessed among 1150 women of Mexican descent enrolled in a case-only, binational breast cancer study. Logistic regression was conducted to compare odds of triple negative breast cancer (TNBC) to non-TNBC according to family history of breast and breast or ovarian cancer among 914 of these women. Prevalence of breast cancer family history in a fi...

A 2011 Pubmed search on the terms “breast cancer” and “triple negative” identified 932 articles, thus interest in this topic since the classification of triple negative/basal-like breast cancer has exploded and a number of recent informative reviews have been published [1–3]. We envision this special edition of Breast Disease focused on triple negative breast cancer (TNBC) as a “go-to” handbook...

BACKGROUND An estimated 1 million cases of breast cancer are diagnosed annually worldwide. Of these, more than 170,000 are described as triple-negative. Triple-negative breast cancer (TNBC) is defined by the lack of protein expression of estrogen receptor (ER) and progesterone receptor (PR) and the absence of HER2 protein overexpression. TNBC is a subtype of breast cancer that overlaps with the...

Tripple negative breast cancer (TNBC) accounts for approximately 15% of breast cancers. It is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER-2 Over expression. Expression of ER, PR and HER-2 plays an important role in therapeutic assessment of patients with breast cancer. TNBC is not one disease, but a family of diseases, some of which are highly aggressiv...

M any physicians consider triple-negative breast cancer (TNBC) the most difficult type to treat, and some patients think it is a death sentence. This subtype of breast cancer is extremely aggressive, has limited treatment options, and carries a high risk of recurrence and death. Unlike breast cancers that express hormone receptors for estrogen and/or pro-gesterone and over-ex press the HER-2/ n...

Triple-negative breast cancer is the most aggressive breast cancer subtype. The aim of our study was to investigate the functional role of both miR-101 and MCL-1 in the sensitivity of human triple-negative breast cancer (TNBC) to paclitaxel. We found that the expression of miR-101 was strongly decreased in triple-negative breast cancer tissues and cell lines. The expression of miR-101 was not a...